Thrombolytic Therapy in Acute Myocardial Infarction

Abstract

Get full access to this article

View all access options for this article.

References

Yusuf S. , Collins R. , Peto R. , et al: Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction, and side effects from 33 randomized trials. Eur Heart J 6:556-563, 1985

DeWood MA , Spores J. , Notske R. , et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902, 1980

Golino P. , Ashton JH , Glas-Greenwalt P. , et al: Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77:678-684, 1988

Hackett D. , Davies G. , Chierchia S. , et al: Intermittent coronary occlusion in acute myocardial infarction . N Engl J Med 317:1055-1059, 1987

Reimer K. , Lowe JE , Rasmussen MM , et al: The wavefront phenomenon of ischemic cell death. Circulation 56:786-794, 1977

Braunwald E. : Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation 79:441-444, 1989 (editorial)

White HD , Norris RM , Brown MA , et al: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76:44-51, 1987

Simoons ML , Vos J. , Tijssen JG , et al: Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Institute of the Netherlands. J Am Coll Cardiol 14:1609-1615, 1989

International Study of Infarct Survival (ISIS) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 . Lancet 2:349-360, 1988

10.

Kennedy JW , Ritchie JL , Davis KB , et al: Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 309:1477-1482,1983

11.

Kennedy JW , Ritchie JL , Davis KB , et al: The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med 312:1073-1078, 1985

12.

Ritchie JL , Davis KB , Williams DL , et al: Global and regional left ventricular function and tomographic radionuclide perfusion: The Western Washington intracoronary streptokinase in myocardial infarction trial. Circulation 70: 867-875, 1984

13.

Dalen JE , Gore JM , Braunwald E. , et al: Six- and twelve-month follow-up of the phase 1 thrombolysis in myocardial infarction (TIMI) trial. Am J Cardiol 62:179-185, 1988

14.

Cigarroa RG , Lange RA , Hillis D. : Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. Am J Cardiol 64:155-160, 1989

15.

Lee KL , Sigmon K. , George BS , et al: Early and complete reperfusion—A key predictor of survival after thrombolytic therapy. Circulation 78:2001, 1988 (suppl 2), (abstr)

16.

Mathey DG , Schofer J. , Sheehan FH , et al: Improved survival up to four years after early coronary thrombolysis . Am J Cardiol 61:524-529, 1988

17.

Rentrop KP , Feit F. , Thornton JC , et al: Does late coronary artery patency in the absence of acute recanalization protect left ventricular function? J Am Coll Cardiol 15:221A, 1990 (abstr)

18.

Gang ES , Lew AS , Hong M. , et al: Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 321:712-716, 1989

19.

Sager PT , Perlmutter RA , Rosenfeld LE , et al: Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 12:19-24, 1988

20.

Lange RA , Cigarroa RG , Wells P. , et al: Influence of anterograde flow in the infarct artery on the incidence of late potentials after acute myocardial infarction. Am J Cardiol 65:554-558, 1990

21.

Shen WF , Cui LQ , Gong LS , et al: Beneficial effect of residual flow to the infarct region on left ventricular volume changes after acute myocardial infarction. Am Heart J 119:525-529, 1990

22.

Van de Werf F. : Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 2:1367-1368, 1989 (editorial)

23.

Tillet WS , Garner RL : The fibrinolytic activity of streptococci. J Exp Med 58:485-489, 1933

24.

Sherry S. : The fibrinolytic activity of streptokinase activated human plasmin . J Clin Invest 33-1054-1060, 1954

25.

Rao AK , Pratt C. , Berke A. , et al: Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988

26.

Chesebro JH , Knatterud G. , Roberts R. , et al: Thrombolysis in myocardial infarction (TIMI) trial: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge . Circulation 76:142-154, 1987

27.

Verstraete M. , Bory M. , Collen D. , et al: Randomized trial of intravenous tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1:842-847, 1985

28.

Hillis LD , Borer J. , Braunwald E. , et al: High dose intravenous streptokinase for acute myocardial infarction: Preliminary results of a multicenter trial. J Am Coll Cardiol 6:957-962, 1985

29.

Monk JP , Heel RC : Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Drugs 34:25-49, 1987

30.

Anderson JL , Rothbard RL , Hackworthy RA , et al: Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 11:1153-1163, 1988

31.

Runge MS , Quertermous T. , Haber E. : Plasminogen activators; The old and the new. Circulation 79:217-224, 1989

32.

Eisenberg PR , Sherman LA , Tiefenbrunn AJ , et al: Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation . Thromb Haemost 57:35-40, 1987

33.

Smalling RW , Schumacher R. , Morris D. , et al: Improved infarct-related artery patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator

34.

in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol 15:915-921, 1990

35.

Mueller HS , Rao AK , Forman SA , et al: Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 10:479-490, 1987

36.

Gold HK , Leinbach RC , Garbedian HD , et al: Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: Prevention by a maintenance infusion . Circulation 73:347-352, 1986

37.

Marder VJ , Rothbard RL , Fitzpatrick PG , et al: Rapid lysis of coronary thrombi with anisoylated plasminogen streptokinase activator complex. Ann Intern Med 104:304-310, 1986

38.

Bonnier HJ , Visser RF , Klomps HC , et al: Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction . Am J Cardiol 62:25-30, 1988

39.

Timmis AD , Griffin B. , Crick JC , et al: Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol 10:205-210, 1987

40.

Mathey DG , Schofer J. , Sheehan FH , et al: Intravenous urokinase in acute myocardial infarction. Am J Cardiol 55:878-882, 1985

41.

Van de Werf F. , Vanhaecke J. , de Geest H. , et al: Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 74:1066-1070, 1986

42.

Diefenbach C. , Erbel R. , Tiberius P. , et al: Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 61:966-970, 1988

43.

Nissen SE , Gurley JC , Grines C. , et al: Observer variability in TIMI flow grading: Comparison to a new computer method for measurement of reperfusion kinetics. J Am Coll Cardiol 13:91, 1989 (suppl) (abstr)

44.

Kircher BJ , Topol EJ , O'Neil WW , et al: Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. Am J Cardiol 59:513-515, 1987

45.

Califf RM , O'Neil W. , Stack RS , et al: Failure of simple clinical measures to predict perfusion status after intravenous thrombolysis. Ann Intern Med 108:658-662, 1988

46.

Miller FC , Krucoff MW , Satler LF , et al: Ventricular arrhythmias during reperfusion. Am Heart J 112:928-932, 1986

47.

Jaffe AS , Sarota H. , Grace A. , et al: Diagnostic changes in plasma creatinine kinase isoforms early after the onset of acute myocardial infarction. Circulation 74:105-109, 1986 47. Wackers FJ , Gibbons RJ , Verani MS , et al: Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: Efficacy for noninvasive assessment of thrombolytic therapy. J Am Coll Cardiol 14:861-873, 1989

48.

White HD , Norris RM , Brown MA , et al: Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 317:850-855,1987

49.

Marino P. , Zanolla P. , Zardini P. , et al: Effect of intravenous streptokinase on left ventricular modeling and function after myocardial infarction: The GISSI trial. J Am Coll Cardiol 14:1149-1158, 1989

50.

National Heart Foundation of Australia Coronary Thrombolysis Group : Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1:203-208, 1988

51.

O'Rourke M. , Baron D. , Keough A. , et al: Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 77:1311-1315, 1988

52.

Armstrong PW , Baigrie RS , Daly PS , et al: Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction . J Am Coll Cardiol 13:1469-1476, 1989

53.

Bassand J. , Machecourt J. , Cassagnes J. , et al: Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Effects on infarct size and left ventricular function. J Am Coll Cardiol 13:988-997, 1989

54.

Braunwald E. , Kloner R. : The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 66:1146-1149, 1982 (editorial)

55.

Gruppo Italiano Per Lo Studio Della Streptokinasi Nell'infarto Miocardico (GISSI): Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI trial. Lancet 1:871-874, 1987

56.

Wilcox RG , Olsson CG , Skene AM , et al: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1:525-530, 1988

57.

AIMS Trial Study Group: Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study. Lancet 335:427-431, 1990

58.

The I.S.A.M. Study Group : A prospective trial of intravenous streptokinase in acute myocardial infarction, mortality, morbidity, and infarct size at 21 days. N Engl J Med 314:1465-1471, 1986

59.

The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 336:71-75, 1990

60.

De Vita C. , Geraci E. , Mauri F. , et al: GISSI-2: Mortality plus extensive left-ventricular damage as "endpoint." Lancet 355:289, 1990 (letter)

61.

Ross AM , Hsia J. , Hamilton W. , et al: Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial. J Am Coll Cardiol 15:64, 1990 (abstr)

62.

Bleich SD , Nichols T. , Schumacher R. , et al: The role of heparin following coronary thrombolysis with tissue plasminogen activator. Circulation 80:455, 1989 (suppl 2) (abstr)

63.

White HD , Rivers JT , Maslowski AH , et al: Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 320:817-821, 1989

64.

Magnani B. for the PAIMS investigators: Plasminogen activator Italian multicenter study (PAIMS) : Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in myocardial infarction. J Am Coll Cardiol 13:19-26, 1989

65.

Hogg KJ , Gemmill JD , Lifson K. , et al: Comparative effects of anistreplase and streptokinase on coronary artery patency in acute myocardial infarction. Circulation 80:1667, 1989 (suppl 2) (abstr)

66.

Anderson JL , Sorenson SG , Moreno F. , et al: Quantitative assessment of coronary stenosis after thrombolysis in acute myocardial infarction: Results of a randomized study of anistreplase and streptokinase. J Am Coll Cardiol 15:218, 1990 (abstr)

67.

Neuhaus K. , Tebbe U. , Gottwik M. , et al: Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German activator urokinase study (GAUS). J Am Coll Cardiol 12:581-587, 1988

68.

Machecourt J. , Cassagnes J. , Bassand JP , et al: Results of a randomized trial comparing APSAC and rt-PA for the preservation of left ventricular function after myocardial infarction. J Am Coll Cardiot 15:64, 1990 (abstr)

69.

Bassand JP , Cassagnes J. , Machecourt J. , et al: A multicenter trial of intravenous APSAC versus rt-PA in acute myocardial infarction; assessment of efficacy and safety. J Am Coll Cardiol 15:214, 1990 (abstr)

70.

The TIMI Study Group : Comparison of invasive and conservitive strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction; Results of the TIMI phase II trial. N Engl J Med 320:618-627, 1989

71.

Tiefenbrunn AJ , Ludbrook PA : Coronary thrombolysis—Its worth the risk. JAMA 261:2107-2108, 1989 (editorial)

72.

George BS , Mayo JR , Candela RJ , et al: Differences in the clinical outcome of patients treated for myocardial infarction using a uniform dose of rt-PA. J Am Coll Cardiol 11:193, 1988 (abstr)

73.

O'Connor CM , Aldrich H. , Massey EW , et al: Intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Clinical characteristics and inhospital outcome. J Am Coll Cardiol 15:213, 1990 (abstr)

74.

Gold HK , Coller BS , Yasuda T. , et al: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77:670-677, 1988

75.

Topol EJ , Ellis SG , Califf RM , et al: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol 14:877-884,1989

76.

Ziskind AA , Gold HK , Yasuda T. , et al: Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Circulation 79:393-399, 1989

77.

Topol EJ , Califf RM , George BS , et al: Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 77:1100-1107, 1988

78.

Tebbe U. , Seifried E. , Feuerer W. , et al: Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 64:448-453, 1989

79.

Neuhaus K. , Feuerer W. , Jeep-Tebbe S. , et al: Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 14:1566-1569, 1989

80.

Topol EJ : Ultrathrombolysis. J Am Coll Cardiol 15:922-924, 1990 (editorial)

81.

Grines CL , Nissen SE , Booth DC , et al: A prospective, randomized trial comparing half dose tPA with streptokinase to full dose tPA in acute myocardial infarction: Preliminary report. J Am Coll Cardiol 15:4, 1990 (abstr)

82.

Sharkey S. , Brunette D. , Ruiz E. , et al: An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 262:3171-3174, 1989

83.

Grim PS , Feldman T. , Childers RW : Evaluation of patients for the need of thrombolytic therapy in the prehospital setting. Annals Emer Med 18:483-488, 1989

84.

Weaver WD , Eisenberg MS , Martin JS , et al: Myocardial infarction triage and intervention project—Phase I: Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 15:925-931, 1990

85.

Kendall GR , Attubato M. , Drew TM , et al: Improved infaret artery patency using a new modified regimen of t-PA: Results of the pre-hospital administration of t-PA (PATS) pilot trial . J Am Coll Cardiol 15:3, 1990 (abstr)

86.

Bossaert LL , Demey HE , Colemont LJ , et al: Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Crit Care Med 16:823-830, 1988

87.

Topol EJ (ed): Thrombolytic intervention, in Textbook of Interventional Cardiology. Philadelphia, PA, Saunders, 1990